BioBridgeX
Log inCompare quotes
Modality

Protein / Enzyme (Recombinant) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a recombinant protein or enzyme means building a biologic in a living expression system (CHO, E. coli, or yeast), then proving it is the right molecule, pure, and stable. Buyers source CRO and CDMO work spanning cell line and process development, analytical and formulation work, GMP drug substance, fill-finish, and immunogenicity testing. On BioBridgeX you compare qualified suppliers as the neutral marketplace, free for buyers, and contract directly with the one you choose.

Protein / Enzyme (Recombinant) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Protein / Enzyme (Recombinant) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Protein / Enzyme (Recombinant) drug?

A recombinant protein or enzyme is not synthesized on a bench the way a small molecule is. It is grown. You insert the gene for your protein into a host cell, then coax that cell to express, fold, and (for many proteins) glycosylate the molecule correctly, and the choice of expression system shapes everything downstream. Mammalian systems, almost always CHO, are the workhorse when you need human-like glycosylation and complex folding, which covers most therapeutic enzymes, fusion proteins, hormones, and cytokines. Microbial systems, E. coli or yeast such as Pichia, are faster and cheaper and fit non-glycosylated proteins, smaller constructs, and many industrial-style enzymes. Picking the wrong host early is one of the more expensive mistakes in this modality, because a switch late in development can mean re-running cell line, process, and a chunk of your analytical work.

Development runs as a chain of linked workstreams, and most programs outsource several of them. Cell line development creates and screens clones for titer, growth, and product quality, then banks a stable master cell bank under GMP. Process development splits into upstream (the bioreactor: media, feed strategy, fed-batch or perfusion, scale-up from shake flask to production scale) and downstream (the purification train: capture chromatography, polishing, viral clearance for mammalian product, and ultrafiltration/diafiltration). Analytical development is unusually heavy for this modality, because a protein has to be characterized for identity, purity, charge and size variants, aggregation, host cell protein and DNA residuals, and for enzymes a validated potency or activity assay that actually tracks the biology. Formulation keeps the protein folded and stable in the vial, and then GMP drug substance manufacturing, fill-finish, and QC release turn the process into clinical and commercial supply.

Where a specialist recombinant protein CDMO pulls away from a generalist is in the parts that punish inexperience. A group that has run many CHO and microbial programs already knows the platform media, the capture resins, the common host cell protein assays, and the viral clearance expectations, so they design the process once rather than learning on your molecule. They have seen aggregation and clipping problems before and have a playbook. For enzymes specifically, a real potency assay (often a kinetic activity assay tied to the mechanism, not just a protein concentration readout) is a capability some generalists simply do not have running. A generalist CDMO can make protein, but the depth in glycan analysis, comparability after a process change, and immunogenicity risk assessment is what separates a clean program from one that stalls at a regulatory review.

How do you choose a CRO or CDMO for Protein / Enzyme (Recombinant)?

Match the supplier to the molecule and the expression system first, then weigh everything else. A site that is excellent at CHO monoclonal-style work is not automatically the right home for a microbial enzyme with refolding and inclusion-body recovery, and the reverse holds too. Score two or three candidates against the same written scope so the quotes measure the same thing, and weight relevant platform experience and analytical depth above headline price, because a comparability failure or a re-run process costs far more than the difference between bids.

  • Relevant platform and track record: confirmed experience in your expression system (CHO, E. coli, or yeast) and your protein class (enzyme, fusion protein, hormone, cytokine), with named programs that reached the clinic or market, not just generic capability claims
  • GxP and analytical capability for this modality: GMP for drug substance and fill-finish, plus the analytical bench this modality demands (identity and sequence confirmation, SEC and aggregation, charge variants, glycan profiling for mammalian product, host cell protein and residual DNA assays, and a validated enzyme potency/activity assay)
  • Capacity and scale: bioreactor scale that fits your phase and a credible path from clinical to commercial volume, current queue and slot availability (often the binding constraint, not the science), and whether single-use or stainless-steel suits your titer and batch size
  • Regulatory experience: a clean FDA and EMA inspection history, comparability protocols for the inevitable process change, viral safety and clearance for mammalian product, and immunogenicity risk assessment, since the immune response to a protein is itself a safety question
  • IP and tech transfer: who owns the cell line and process know-how, whether any expression platform or host carries licensing or royalty strings, and how cleanly the cell bank, process, and analytical methods transfer out if you move sites or scale up elsewhere

Frequently asked questions

What is the difference between making a recombinant protein in CHO versus E. coli?
The host decides what you can make and how you make it. CHO (a mammalian line) folds complex proteins and adds human-like glycosylation, so it suits therapeutic enzymes, fusion proteins, and most secreted proteins, but it is slower, lower titer per unit time historically, and needs viral clearance in the purification train. E. coli is fast, cheap, and high-expressing, and fits non-glycosylated proteins and smaller constructs, but product often lands in inclusion bodies that require refolding, and it cannot glycosylate. Yeast such as Pichia sits in between. Choose the host for the molecule's biology first, because switching hosts late forces you to repeat cell line, process, and analytical work.
How do you assess immunogenicity for a recombinant protein or enzyme?
Because a therapeutic protein is a foreign molecule, the body can raise anti-drug antibodies (ADA) that neutralize activity or, in the worst cases, cross-react with an endogenous protein. Assessment usually combines in silico and in vitro risk prediction during development with validated ADA and neutralizing-antibody assays in nonclinical and clinical samples. Product-quality drivers matter here too: aggregation, host cell protein residuals, and glycan differences can all raise immunogenic risk, which is one reason analytical control is so central for this modality. A CRO or CDMO with real immunogenicity experience builds these assays early rather than retrofitting them.
Should I use one CDMO for the whole protein program or split the work?
Both models are common. An end-to-end CDMO that takes the program from cell line through GMP drug substance and fill-finish gives you one point of accountability and a cleaner tech-transfer story, which a lean biotech often values. Splitting work (one group for cell line and process development, another for GMP manufacturing, a specialist lab for glycan or potency analytics) lets you pick the best supplier per workstream but pushes coordination and tech transfer onto you. The trade-off is control versus overhead. On BioBridgeX you can run either model and still contract once across every supplier, which removes most of the coordination tax from the split-supplier approach.
Why is analytical development such a large part of a recombinant protein program?
A protein is a big, heterogeneous molecule, so proving you made the right one (and the same one batch after batch) takes a deep analytical package. You characterize identity and sequence, size and charge variants, aggregation, glycosylation for mammalian product, and residual impurities like host cell protein and DNA, plus a potency assay that reflects the protein's actual function. For an enzyme that means a validated activity assay tied to the catalytic mechanism, not just a concentration measurement. This package also underpins comparability, the data that shows your product is unchanged after a process improvement or a site move, which regulators will ask for. Underbuilding analytics early is a frequent cause of delays later.
How long does it take to develop and manufacture a recombinant protein?
Treat any single number with caution, because it swings with the host, the molecule, and how much process work is already done. As rough orientation, cell line development and banking commonly runs several months, process and analytical development several more, and GMP manufacturing of a drug substance batch plus fill-finish and release adds further months on top, so reaching clinical supply is typically a matter of many months to well over a year from a standing start. Booking GMP manufacturing slots early is usually the biggest lever on the calendar, since slot availability, not the science, is the common bottleneck.
Is sourcing protein and enzyme CDMO services on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers and acts as the neutral marketplace, owning no manufacturing capacity of its own, so it has no reason to steer your program toward a preferred site. Suppliers pay a flat 2 percent success fee after the buyer pays them. When you split a protein program across suppliers (say a process development group, a GMP drug substance CDMO, and a specialist analytical lab) you compare quotes and contract directly with each chosen supplier in one place, and coverage spans every indication and modality so the same account carries forward as the program advances.

Source Protein / Enzyme (Recombinant) work with one contract

Compare transparent quotes from qualified Protein / Enzyme (Recombinant) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes